Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
Healthcare | Drug Manufacturers - Major | USA
financial highlights | statements
IndexDJIA S&P500 P/E22.93 EPS (ttm)3.71 Insider Own0.10% Shs Outstand2.57B Perf Week-0.54%
Market Cap218.94B Forward P/E15.62 EPS next Y5.45 Insider Trans-27.38% Shs Float2.56B Perf Month2.87%
Income9.72B PEG2.26 EPS next Q1.23 Inst Own78.90% Short Float0.74% Perf Quarter8.05%
Sales44.37B P/S4.93 EPS this Y33.00% Inst Trans0.46% Short Ratio1.85 Perf Half Y6.58%
Book/sh10.74 P/B7.92 EPS next Y11.21% ROA11.20% Target Price94.36 Perf Year26.26%
Cash/sh2.76 P/C30.82 EPS next 5Y10.17% ROE32.80% 52W Range66.10 - 87.07 Perf YTD11.32%
Dividend2.20 P/FCF91.69 EPS past 5Y10.60% ROI11.70% 52W High-2.31% Beta0.56
Dividend %2.59% Quick Ratio0.90 Sales past 5Y-0.80% Gross Margin71.10% 52W Low28.68% ATR1.65
Employees69000 Current Ratio1.20 Sales Q/Q12.40% Oper. Margin26.70% RSI (14)55.04 Volatility1.76% 1.80%
OptionableYes Debt/Eq0.96 EPS Q/Q62.90% Profit Margin21.10% Rel Volume0.85 Prev Close83.46
ShortableYes LT Debt/Eq0.82 EarningsJul 30 BMO Payout59.20% Avg Volume10.25M Price85.06
Recom1.70 SMA202.09% SMA501.90% SMA2007.49% Volume8,673,396 Change1.92%
Aug-16-19Initiated SVB Leerink Outperform
Jul-03-19Initiated Mizuho Buy $97
May-28-19Initiated Goldman Neutral
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-16-19 11:28AM  Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY Zacks
10:33AM  AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL Zacks
09:00AM  Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC Zacks
06:20AM  Gene therapies to test FDA's approach to regulating drugs after launch, experts say American City Business Journals
Aug-15-19 03:36PM  The Top Pharma Stocks for 2019 Investopedia
07:55AM  Moleculin Completes Enrollment in Early-Stage Cancer Study Zacks
07:48AM  Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth Zacks
06:32AM  New CEO named for Moffitt startup M2Gen American City Business Journals
Aug-14-19 04:32PM  Article removed GuruFocus.com
06:55AM  LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer Business Wire
Aug-13-19 09:15AM  Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice Zacks
07:27AM  GSK's new pharma president carries Merck, Pfizer experience American City Business Journals
06:00AM  An Intrinsic Calculation For Merck & Co., Inc. (NYSE:MRK) Suggests It's 22% Undervalued Simply Wall St.
Aug-12-19 07:15PM  Merck & Co Inc (MRK) EVP&Pres, Merck Animal Heallth Richard R. Deluca Sold $3. ... GuruFocus.com
12:10PM  Bristol-Myers Squibb Stock Has Upside But Mind the Risks InvestorPlace
09:30AM  J&J's Tuberculosis Drug Gets FDA Nod for Adolescent Patients Zacks
06:30AM  BriaCell Appoints Richard J. Berman to Board of Directors GlobeNewswire
Aug-09-19 10:59AM  Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2 Zacks
10:04AM  Risk-Takers Have a Reasonable Shot with BMY Stock InvestorPlace
09:27AM  Novo Nordisk (NVO) Q2 Earnings & Revenues Beat Estimates Zacks
08:06AM  Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat Zacks
Aug-08-19 04:03AM  Merck KGaA CFO: Good Market Conditions Will Prevail Bloomberg
01:15AM  Merck KGaA's Q2 profit bolstered by drug milestone payments Reuters
Aug-07-19 04:39PM  Merck Announces Leadership Changes to Investor Relations Team Business Wire
11:15AM  Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y Zacks
06:55AM  LYNPARZA® (olaparib) Phase 3 PROfound Trial in HRR Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint Business Wire
Aug-06-19 05:26PM  Kahn Brothers' Top 6 Buys in the 2nd Quarter GuruFocus.com
02:29AM  Fear Around Bristol-Myers Squibb Stock is Starting to Fade InvestorPlace
Aug-05-19 11:36AM  Top Stock Reports: Mastercard, Verizon, Coca-Cola & More Zacks
10:46AM  Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates Zacks
Aug-04-19 09:00AM  These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024 Motley Fool
Aug-03-19 10:25AM  Bulls And Bears Of The Week: Boeing, GM, Pfizer, Starbucks And More Benzinga
Aug-02-19 01:56PM  David Carlson Goes 2 for 2 in 2nd Quarter GuruFocus.com
09:54AM  Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger Zacks
Aug-01-19 09:30AM  Has Merck & Co. (MRK) Outpaced Other Medical Stocks This Year? Zacks
Jul-31-19 05:32PM  Big Bay Area biotech developer on buying binge as others enter 'funky, oddball niche' American City Business Journals
11:18AM  Stocks - Stocks Dive as Fed's Powell Sinks Future Easing Hopes Investing.com
09:54AM  Stock Market News For Jul 31, 2019 Zacks
09:15AM  Rate Cut Wait Almost Over Zacks
06:45AM  FDA Approves New Monotherapy Indication for Mercks KEYTRUDA® (pembrolizumab) Business Wire
Jul-30-19 09:35PM  Edited Transcript of MRK earnings conference call or presentation 30-Jul-19 12:00pm GMT Thomson Reuters StreetEvents
06:21PM  US Indexes Close Mostly Lower Tuesday GuruFocus.com
04:28PM  Stocks end lower as China trade deal hopes wane and corporate earnings come in mixed MarketWatch
03:00PM  Merck Reports Fantastic Q2 Earnings Results: 4 Things You Need to Know Motley Fool
01:14PM  Merck Shares Rise on Strong Sales Growth GuruFocus.com
12:49PM  Merck (MRK) Beats on Q2 Earnings & Sales, Raises '19 View Zacks
12:23PM  Merck & Co Inc (MRK) Q2 2019 Earnings Call Transcript Motley Fool
11:22AM  Merck Stock Tests Risky Level on Earnings Beat Investopedia
10:53AM  Economic and Earnings Date Deluge Zacks
10:45AM  Stock Market News: Proctor & Gamble, Merck Can't Buoy Benchmarks Motley Fool
10:34AM  Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More Zacks
10:30AM  Merck Calls Heat Up on Earnings Beat, Guidance Boost Schaeffer's Investment Research
10:23AM  US STOCKS-Wall Street drops as trade tensions weigh, Fed meeting looms Reuters
10:06AM  Stock Market News For Jul 30, 2019 Zacks
09:32AM  Merck Crushes Quarter; Cancer Drug on Track for $10 Billion a Year Bloomberg
09:08AM  US STOCKS-Wall St set to open lower as focus shifts to Fed meeting, Apple earnings Reuters
08:22AM  Merck quarterly profit beats on strong demand for Keytruda, vaccines Reuters
07:55AM  Merck (MRK) Beats Q2 Earnings and Revenue Estimates Zacks
07:27AM  Merck Reports Q2 Earnings Beat Benzinga
07:21AM  Merck raises forecasts as cancer drug sales soar Financial Times
07:13AM  Merck profit beats on strong demand for Keytruda, vaccines Reuters
07:00AM  The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings Benzinga
06:45AM  Merck Announces Second-Quarter 2019 Financial Results Business Wire
04:28AM  Stocks - Beyond Meat, Capital One, Under Armour Fall Premarket; Merck Rises Investing.com
02:47AM  Merck&Co Earnings, Revenue Beat in Q2 Investing.com
Jul-29-19 05:12PM  What Happened in the Stock Market Today Motley Fool
04:05PM  Merck Receives Positive EU CHMP Opinion for ZERBAXA® 3g Dose (ceftolozane and tazobactam) for the Treatment of Adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP) Business Wire
03:05PM  Pfizer to Combine Off-Patent Drug Business With Mylan GuruFocus.com
02:43PM  Enticing development: Why Merck's expansion means good news for Durham American City Business Journals
02:38PM  Merck Q2 Earnings Preview Benzinga
09:30AM  Merck's Keytruda Gets A Double Dose Of Positive News Benzinga
06:55AM  Mercks KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Pathological Complete Response (pCR) in Pivotal Phase 3 KEYNOTE-522 Trial in Patients with Triple-Negative Breast Cancer (TNBC) Business Wire
06:30AM  European Medicines Agency Adopts Positive Opinion for Mercks KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma Business Wire
Jul-28-19 10:16PM  Alpharetta health tech data company raises $30 million American City Business Journals
Jul-26-19 11:22AM  Senate advances bill to cut the cost of prescriptions Yahoo Finance Video
09:15AM  Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy? Zacks
08:39AM  Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment Zacks
Jul-25-19 06:52PM  Buy Merck & Co (MRK) Stock Ahead of Q2 Earnings Report? Zacks
12:10PM  In one release, Merck states laying off 150 and adding 400+ American City Business Journals
10:45AM  Bristol-Myers (BMY) Beats on Q2 Earnings & Sales, Raises View Zacks
10:32AM  UPDATE 2-Eliquis, Orencia sales propel Bristol-Myers to strong second quarter Reuters
10:26AM  AstraZeneca (AZN) Q2 Earnings Top, '19 Product Sales View Up Zacks
09:24AM  Jobs! Gardasil maker to bring 425 jobs to Triangle region American City Business Journals
07:00AM  Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise Reuters
Jul-24-19 04:44PM  Bristol-Myers Shares Sputter After Setback for Top Cancer Drug Bloomberg
01:54PM  What to Expect from Sanofi's (SNY) Q2 Earnings (Revised) Zacks
12:13PM  What to Expect from Sanofi's (SNY) Q2 Earnings Zacks
11:00AM  Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019 Business Wire
09:44AM  Large-Cap Pharmaceuticals Industry Near-Term Outlook Bright Zacks
09:34AM  Merck (MRK) to Report Q2 Earnings: What's in the Cards? Zacks
12:15AM  Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q2 Earnings? Zacks
Jul-23-19 05:41PM  CORRECTED-Samsung Bioepis Humira biosimilar wins FDA approval Reuters
02:03PM  Why Bristol-Myers Squibb Stock Is Stumbling Ahead of Earnings InvestorPlace
12:54PM  Merck Announces Fourth-Quarter 2019 Dividend Business Wire
11:36AM  What Investors Should Know About Merck & Co., Inc.'s (NYSE:MRK) Financial Strength Simply Wall St.
11:00AM  Merck Presents Early Evidence on Extended Delivery of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) via Subdermal Implant Business Wire
10:32AM  Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
09:25AM  Eisai's Cancer Drug Combo Gets Breakthrough Therapy Designation For Liver Cancer Benzinga
06:45AM  Merck and Eisai Receive Third Breakthrough Therapy Designation from FDA for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment Business Wire
06:30AM  BriaCell Announces $350,000 Equity Investment by Board of Directors GlobeNewswire
Merck & Co., Inc. provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, and cervical cancer, as well as brain tumors; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; fertility management products for horses; vaccines for dogs, cats, and horses; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Intec Pharma Ltd.; Nerviano Medical Sciences; and Healthy Interactions, Inc. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Option Exercise0.006,427077,951Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Sale85.096,427546,85071,524Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Option Exercise0.0031,6990103,223Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Sale85.0131,6992,694,78971,524Aug 12 05:13 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Option Exercise0.00216,7180354,378Jun 27 05:05 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Sale85.43216,71818,514,032137,660Jun 27 05:05 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 10Option Exercise0.003,292022,412May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 10Option Exercise0.004,389071,993May 13 05:05 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 10Option Exercise0.001,50903,317May 13 05:05 PM
Nally MichaelEVP, Chief Marketing OfficerMay 10Option Exercise0.001,81104,376May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Option Exercise39.2925,000982,25092,604May 09 06:11 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Sale77.7325,0001,943,18367,604May 09 06:11 PM
Zachary JenniferEVP, General CounselMay 04Option Exercise0.005,77205,772May 07 07:42 PM
Nally MichaelEVP, Chief Marketing OfficerMay 04Option Exercise0.001,29802,935May 07 07:40 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise0.001,904068,542May 07 07:37 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise0.001,212019,717May 07 08:32 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 04Option Exercise0.0069202,046May 07 08:32 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Option Exercise39.2935,0001,375,150106,064May 07 08:33 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Sale80.0035,0002,800,00071,064May 07 08:33 PM
Merck & Co., Inc.10% OwnerApr 08Buy16.004,121,68365,946,92812,955,016Apr 09 06:27 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Option Exercise58.22192,57211,211,542330,232Mar 27 05:45 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Sale82.38192,57215,863,119137,660Mar 27 05:45 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Option Exercise39.29192,7367,572,597990,451Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Sale82.05192,73615,813,372797,715Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Option Exercise39.2918,725735,705816,440Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Sale82.0018,7251,535,454797,715Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Option Exercise39.296,961273,498804,676Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Sale82.006,961570,809797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Option Exercise39.2913,144516,428810,859Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Sale82.0113,1441,077,875797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Option Exercise39.2953,9612,120,128745,911Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Sale80.0253,9614,318,089691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Option Exercise39.2941,9921,649,866733,942Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Sale80.0041,9923,359,452691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Option Exercise39.2942,7001,677,683734,650Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Sale80.0242,7003,416,944691,950Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Option Exercise39.2992,9133,650,552784,863Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Sale80.0392,9137,436,162691,950Feb 19 05:35 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Option Exercise59.1664,6623,825,55180,837Feb 14 06:02 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale78.9664,6625,105,95116,175Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Option Exercise24.305,000121,5005,100Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Sale78.715,000393,548100Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Option Exercise38.1873,7272,815,241125,194Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Sale78.6273,7275,796,30651,467Feb 14 06:02 PM
BRUN LESLIE ADirectorFeb 08Option Exercise24.305,000121,5005,000Feb 11 05:33 PM
BRUN LESLIE ADirectorFeb 08Sale77.223,052235,6811,948Feb 11 05:33 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Option Exercise39.29231,5669,098,228923,516Feb 06 05:30 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Sale78.08231,56618,079,654691,950Feb 06 05:30 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Option Exercise44.98225,44310,140,426366,998Nov 08 04:31 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Sale75.27225,44316,967,967141,555Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise54.6836,2181,980,40082,481Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale75.1436,2182,721,34846,263Nov 08 04:31 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Option Exercise39.29277,87910,917,866277,879Nov 02 04:44 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Sale73.81277,87920,510,9450Nov 02 04:44 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Option Exercise58.3647,0362,745,21756,806Nov 01 05:07 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Sale74.3347,0363,496,1589,770Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Option Exercise34.1925,467870,71782,135Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Sale72.0025,4671,833,73956,668Nov 01 05:07 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Option Exercise36.56279,85010,231,316971,800Oct 03 05:26 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Sale72.07279,85020,168,258691,950Oct 03 05:26 PM
Merck & Co., Inc.10% OwnerOct 01Buy15.00666,6669,999,9902,723,509Oct 02 02:31 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Option Exercise36.56279,85110,231,353971,801Sep 19 05:43 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Sale70.08279,85119,611,818691,950Sep 19 05:43 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Option Exercise36.56100,0003,656,000100,000Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.187,360516,51155,406Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.18100,0007,017,7800Sep 18 04:49 PM
open in yahoo | open in reuters | open in google